The European Commission needs to prioritise equitable access to biosimilar medicines in Europe

25 January 2022

Over 15 years ago, the world’s first biosimilar was launched. […]

Regulatory reforms critical to improve patient access to medicines

24 January 2022

The ongoing review of the EU pharmaceutical legislation framework is […]

EU pharmaceutical legislation must support a competitive off-patent industry to deliver equitable access to medicines

20 December 2021

Strong support for new measures to protect patient access to medicines in Northern Ireland

20 December 2021

Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health

15 December 2021

Commission study highlights market framework conditions are main driver for medicines shortages

9 December 2021

Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries

26 November 2021

European Parliament report calls for increased use of off-patent medicines to improve patient access

24 November 2021

The EU must stop the offshoring of essential medicines manufacturing investments

23 November 2021

Adjustments to IP framework needed to improve access to medicines in Europe

16 November 2021

Access to generic and biosimilar medicines can be improved with coherent proposals for IP […]